

**OptiBiotix Health plc
("OptiBiotix" or the "Company")**

**Non-Exclusive License Agreement with HiLife Vitamins for SlimBiome®
Medical in the USA**

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered in to a non exclusive license agreement for SlimBiome® Medical with HiLife Vitamins & Herbs Co Inc ("HiLife"). The agreement grants HiLife non-exclusive rights to commercialise OptiBiotix's SlimBiome® Medical proprietary weight management product in the USA.

HiLife (<https://hilifevitamins.com>) is an established online health supplement retailer based in the USA. HiLife is a privately owned business founded in 1971 supplying its local community with healthy supplements. With the evolution of e-commerce HiLife rapidly extended its customer base becoming one of the first online health supplement retailers in the USA. Nearly fifty years on, HiLife lists over 5000+ products online having built an established and loyal customer base across the USA.

The signing of this agreement was subject to the placing of a trial order and a six month period after which both parties will discuss the terms of the agreement to explore online exclusivity for the USA. These discussions will follow a review of sales performance over the period. Any subsequent exclusivity agreed will be linked to minimum order quantities. Discussions to explore the manufacturing of SlimBiome® Medical locally in the USA will also take place with the aim of reducing logistical and import costs as volumes increase.

This is another strategic step by OptiBiotix to commercialise its award-winning technology on an international stage in a major market. With the Company exploring listings in international markets, increasing global brand exposure both as an ingredient and as a finished product in retailers and online enhance the awareness of OptiBiotix's scientific and commercially validated technologies.

Thomas O'Hara, Business Development Manager at Optibiotix, commented: *"We are pleased to have signed an agreement with HiLife to commercialise our award-winning weight management technology in such a large and key market for weight management products. HiLife contacted us expressing an interest in our product portfolio underlining the recognition and reputation OptiBiotix is establishing in major markets. We are pleased to inform our existing US*

customer base that SlimBiome® Medical can now be locally purchased in the USA online at: <https://hilifevitamins.com/products/slimbiome-medical-060609990190>."

Susan Rubin, Owner at HiLife, commented: "We are honored and proud to have signed an agreement with Optibiotix. With a strong local and e-commerce presence, HiLife Vitamins saw a tremendous opportunity to bring patented award-winning weight management products into the US. As we are expanding our product selections for our customers, we wanted to bring something unique to the US market. Slimbiome® Medical is a clinically proven, science-backed natural supplement to aid with effective weight management. We welcome all US customers to now purchase Slimbiome® Medical at our official website: www.Hilifevitamins.com."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc

Stephen O'Hara, Chief Executive

www.optibiotix.com

Contact via Walbrook
below

Cairn Financial Advisers LLP (NOMAD)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

Geoff Nash / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited

Ulrich Kinzel

Tel: 0203 859 7725

Walbrook PR Ltd

Anna Dunphy

Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRDZGZLVMZGGZM